Clastogenic ROS and biophotonics in precancerous diagnosis

Naveed, Muhammad; Raees, Muhammad; Liaqat, Irfan; Kashif, Mohammad

doi:10.1007/s11515-018-1488-0

Cited by 5 publications

(4 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reactions involving ROS in living tissues, including all animals and plants, have been shown to cause the continuous release of photons from mitochondria, which are emitted as excited electrons return to the ground state (60)(61)(62)(63)(64)(65)(66)(67)(68)(69). These biophotons are primarily in the ultraviolet and visible ranges (100-800 nm), but may also extend to the infrared (70,71). Measurements of photon release have been used to monitor ROS production (72).…”

Section: Mitochondrial Biophoton Emissionmentioning

confidence: 99%

The Mystery of Chemotherapy Brain: Kynurenines, Tubulin and Biophoton Release

Sordillo

2020

Anticancer Res

View full text Add to dashboard Cite

The majority of patients receiving chemotherapy experience post-chemotherapy cognitive impairment, sometimes referred to as "chemo brain" or "chemo fog." The cognitive impairment associated with this syndrome can be severe, and can sometimes last for many years after therapy discontinuation. Despite extensive investigations, its etiology is unknown. We argue that chemo brain results from damage to tubulin within microtubules. This damage can occur directly from tubulin inhibitors such as taxanes, epothilones or vinca alkaloids. Other chemotherapies stimulate increased mitochondrial activity and biophoton release. This results in abnormal tryptophan metabolism and excess production of neurotoxic kynurenines, which, in turn, damage microtubules.

show abstract

Section: Mitochondrial Biophoton Emissionmentioning

confidence: 99%

The Mystery of Chemotherapy Brain: Kynurenines, Tubulin and Biophoton Release

Sordillo

2020

Anticancer Res

View full text Add to dashboard Cite

show abstract

“…A balance between endogenous ROS and antioxidants is important to maintain cellular functions, while excessive ROS generation or lowered levels of antioxidants can cause damage to cells and tissues, leading to diseases including cancer, diabetes, arthritis, etc . Consequently, effective imaging agents for ROS may help better diagnose ROS‐relevant diseases with spatiotemporal precision due to the sensitivity and simplicity of fluorescence‐based techniques for biomedical applications . The following subsections will focus on recently developed fluorescence imaging agents that achieve intracellular and, especially, in vivo imaging of disease‐relevant ROS.…”

Section: Fluorescent Imaging Agents For Diagnosis Of Ros‐relevant Dismentioning

confidence: 99%

“…With the rapid development of fluorescence‐based imaging techniques, in vivo imaging of ROS was achieved in live animals . As a result, these fluorescence‐based methods have the potential for clinical diagnosis, prediction of drug efficacy and prognosis of ROS‐related diseases as well as facilitating the understanding of the precise role played by ROS in a specific disease …”

Section: Introductionmentioning

confidence: 99%

Sensors, Imaging Agents, and Theranostics to Help Understand and Treat Reactive Oxygen Species Related Diseases

et al. 2019

View full text Add to dashboard Cite

Reactive oxygen species (ROS) consist of a diverse range of oxidative small molecular ions and free radicals that are produced throughout the body during certain biological processes. Due to their high reactivity, these molecules result in the damage of tissues and cells. Therefore, ROS have been implicated in an array of diseases including cancer, inflammation, and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. Owing to the simplicity, sensitivity, and selectivity of fluorescence‐based strategies, many small‐molecular sensors or imaging agents have been developed to sense and visualize ROS both in vitro and in vivo. Likewise, activatable drug delivery and prodrug systems that can be triggered by ROS for disease theranostics (diagnostic and therapeutic combined) have been developed. Herein, recently developed fluorescence‐based sensing and imaging agents for the detection of ROS both intracellularly and in vivo are summarized. In addition, drug delivery, which require activation by ROS to achieve disease theranostics is also discussed.

show abstract

“…Second, turn-on-type, near-infrared (NIR) fluorescent probes are rare owing to the lack of NIR fluorophores that are stable in the presence of OCl – . Additionally, practical applications of probes developed for the detection of OCl – -related diseases have not been fully investigated. , Interdisciplinary collaborations of chemists, biologists, and therapeutists are required to address these issues. In this Account, we introduce general principles involved in the design of probes for OCl – and the results of recent efforts aimed at expanding the range of fluorescent chemosensors for this ROS and their application in imaging.…”

Section: Introductionmentioning

confidence: 99%

Design Principles, Sensing Mechanisms, and Applications of Highly Specific Fluorescent Probes for HOCl/OCl^–

et al. 2019

View full text Add to dashboard Cite

Hypochlorous acid/hypochlorite (HOCl/ OCl − ), one of the most important reactive oxygen species (ROS), plays vital roles in various physiological and pathological processes. At normal concentrations, OCl − acts as part of an immune defense system by destroying invasive bacteria and pathogens. However, nonproperly located or excessive amounts of OCl − are related to many diseases, including cancers. Thus, detection of OCl − has great importance. Owing to their high sensitivities, selectivities, fast response times, technical simplicities, and high temporal and spatial resolution, fluorescent probes are powerful tools for in vitro and in vivo sensing of target substances. This Account focuses on the development of new chemosensors for detection of OCl − , which operate by undergoing a chemical reaction with this ROS in conjunction with a change in emission properties. As part of the presentation, we first introduce several important factors that need to be considered in the design of fluorescent chemosensors for OCl − , including fluorophores, reaction groups, cosolvents, and buffers. Discussion here revolves around the need to select fluorophores that resist oxidation by OCl − . As well, attention is given to the sensitivities and selectivities of groups in the sensors that react with OCl − to trigger a fluorescence response. Moreover, well-known reaction groups, which react with highly reactive ROS (hROS), have been redesigned to be specific for OCl − . In addition, it is pointed out that several cosolvents and buffers such as DMSO and HEPES are not suitable for use in systems for the detection of OCl − because they are readily oxidized by this ROS. We further discuss recent investigations carried out by us and others aimed at the development of fluorescent probes for in vitro and in vivo detection of OCl − . These efforts led to the new "dual lock" strategy for designing OCl − chemosensors as well as several new specific reaction groups such as imidazoline-2-thiones and imidazoline-2-boranes. Probes created using this strategy and the new reacting groups have been successfully applied to imaging exogenous and endogenous OCl − in live cells and/or tissues. The design concepts and strategies emanating from our studies of fluorescent OCl − probes have provided insight into the general field of fluorescent probes. Despite the progress made thus far, challenges still remain in developing and applying fluorescent OCl − probes. For example, more highly specific and sensitive fluorescent OCl − probes are still in great demand for studies of the biological roles played by OCl − . Thus, interdisciplinary collaborations of chemists, biologists, and medical practitioners are needed to drive future developments of OCl − probes for disease diagnosis and drug screening.

show abstract

Clastogenic ROS and biophotonics in precancerous diagnosis

Cited by 5 publications

References 81 publications

The Mystery of Chemotherapy Brain: Kynurenines, Tubulin and Biophoton Release

The Mystery of Chemotherapy Brain: Kynurenines, Tubulin and Biophoton Release

Sensors, Imaging Agents, and Theranostics to Help Understand and Treat Reactive Oxygen Species Related Diseases

Design Principles, Sensing Mechanisms, and Applications of Highly Specific Fluorescent Probes for HOCl/OCl^–

Contact Info

Product

Resources

About

Clastogenic ROS and biophotonics in precancerous diagnosis

Cited by 5 publications

References 81 publications

The Mystery of Chemotherapy Brain: Kynurenines, Tubulin and Biophoton Release

The Mystery of Chemotherapy Brain: Kynurenines, Tubulin and Biophoton Release

Sensors, Imaging Agents, and Theranostics to Help Understand and Treat Reactive Oxygen Species Related Diseases

Design Principles, Sensing Mechanisms, and Applications of Highly Specific Fluorescent Probes for HOCl/OCl–

Contact Info

Product

Resources

About

Design Principles, Sensing Mechanisms, and Applications of Highly Specific Fluorescent Probes for HOCl/OCl^–